Company: NCEL
Filing Date: 2025-01-16
Form Type: 425
Source: 0001213900-25-004028
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-01-16
Form: 425
Chunk 2
---
SEC), outlining the details of the proposed merger.

Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics, stated,
“We are excited about approaching completion of the merger with Kadimastem. This significant step not only demonstrates our commitment
to innovation but also holds great potential for delivering enhanced value to our shareholders. Together, we believe that we are poised
to redefine the landscape of biotechnology and patient care.”

Ronen Twito, Executive Chairman and Chief Executive Officer of Kadimastem, commented, “We are pleased to be taking this crucial step toward completing our merger with NLS . We are eager to engage our
shareholders in this process as we believe this merger will create a powerful entity in the biotechnology sector, unlocking new opportunities
for growth and advancement in innovative therapies.”

About NLS Pharmaceutics Ltd.

NLS is a global development-stage biopharmaceutical company,
working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of
innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in
Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product
candidates. For more information, please visit www.nlspharma.com.

About Kadimastem

Kadimastem is a clinical stage cell therapy company, developing “off-the-shelf”,
allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells
(hESCs) into functional cells. AstroRx®, the company’s lead product, is an astrocyte cell therapy in clinical development for
the treatment for ALS and in pre-clinical studies for other neurodegenerative indications.

IsletRx is the company’s treatment for diabetes. IsletRx is comprised
of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with
insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem and Professor Emeritus
of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development
of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).

Safe Harbor Statement

This press release contains expressed or implied forward-looking